Vilon vs Syn-Ake
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Vilon is a synthetic dipeptide (Lys-Glu) derived from the thymus gland extract Thymalin. The shortest immune-regulatory peptide known, Vilon modulates T-cell and NK-cell function, extends lifespan in animal models, and shows epigenetic anti-aging activity. It is one of the Khavinson peptide bioregulators.
- Syn-Ake is a synthetic tripeptide that mimics waglerin-1, a peptide found in the venom of the Temple viper (Tropidolaemus wagleri). It acts as a reversible antagonist of muscular nicotinic acetylcholine receptors, temporarily reducing facial muscle contraction and smoothing dynamic wrinkles. Often called a 'synthetic Botox' in cosmetic marketing.
- Half-Life
- Very short as a free dipeptide; effects mediated via gene regulation
- Not applicable (topical; effect duration hours)
- Admin Route
- SubQ, Oral
- Topical
- Research
- —
- —
- Typical Dose
- 1–2 mg SC daily or 5–10 mg oral daily
- 0.01–0.1% (4–8 mg/g in clinical studies)
- Frequency
- Once daily
- Twice daily
- Key Benefits
- Immune system modulation and restoration
- Lifespan extension (30–40% in animal studies)
- T-cell and NK-cell activation
- Epigenetic anti-aging activity
- Reduces oxidative stress markers
- Antioxidant gene upregulation
- May prevent age-related immune senescence
- Anti-tumor immune surveillance
- Reduces depth of dynamic wrinkles and expression lines
- Reversible muscle-relaxing effect on facial muscles
- Smooths forehead lines, crow's feet, and frown lines
- Non-invasive alternative to injectable neurotoxins
- Rapid onset relative to collagen-stimulating peptides
- Well-studied in in vitro and clinical cosmetic trials
- Side Effects
- Excellent safety profile, decades of Russian clinical use
- Rare: mild injection site reaction
- Very rare: mild allergic reaction
- Generally very well-tolerated topically
- Rare skin sensitivity or contact dermatitis
- Theoretical neuromuscular effects at systemic doses (not relevant topically)
- Stacks With
- —
- —